Cubist Systematic Strategies’s BridgeBio Pharma BBIO Stock Holding History

Cubist Systematic Strategies’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$1.49M	Buy	+28,668	New	+$1.4M	0.01%	1740
2024 Q1	–	Sell	-11,511	Closed	-$391K	–	3710
2023 Q4	$465K	Buy	+11,511	New	+$346K	﹤0.01%	2560
2023 Q3	–	Sell	-185,063	Closed	-$5.25M	–	3338
2023 Q2	$3.18M	Sell	185,063 -33,583	-15%	-$505K	0.02%	1132
2023 Q1	$3.63M	Buy	218,646 +211,721	+3,057%	+$2.47M	0.02%	1188
2022 Q4	$52.8K	Sell	6,925 -452,011	-98%	-$4.33M	﹤0.01%	3896
2022 Q3	$4.56M	Buy	458,936 +217,940	+90%	+$2.26M	0.03%	1162
2022 Q2	$2.19M	Sell	240,996 -5,735	-2%	-$48K	0.01%	1771
2022 Q1	$2.5M	Buy	246,731 +183,439	+290%	+$1.88M	0.02%	1297
2021 Q4	$1.06M	Buy	63,292 +51,656	+444%	+$2.19M	0.01%	1871
2021 Q3	$545K	Buy	+11,636	New	+$624K	0.01%	1977
2021 Q2	–	Sell	-3,738	Closed	-$230K	–	2919
2021 Q1	$230K	Sell	3,738 -4,188	-53%	-$274K	﹤0.01%	2392
2020 Q4	$564K	Sell	7,926 -20,875	-72%	-$1.01M	0.01%	1705
2020 Q3	$1.08M	Buy	+28,801	New	+$906K	0.02%	1285

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cubist Systematic Strategies's BBIO Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in BridgeBio Pharma (BBIO) in Q3 2025: 28,668 shares worth $1.49M. The stake represents 0.01% of the portfolio and ranks #1740 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in BBIO as recently as Q4 2023.

Cubist Systematic Strategies first reported a position in BBIO in Q3 2020 and has held it in 13 quarters since. The position peaked at $4.56M in Q3 2022. 392 funds tracked by Wall St. Rank hold BBIO as of Q3 2025.

Cubist Systematic Strategies held 28,668 shares of BridgeBio Pharma worth $1.49M as of Q3 2025.
BridgeBio Pharma was a new Cubist Systematic Strategies position in Q3 2025.
BridgeBio Pharma made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1740 holding.
Cubist Systematic Strategies first reported a position in BridgeBio Pharma in Q3 2020 and has held it in 13 quarters since.
Cubist Systematic Strategies's BridgeBio Pharma position peaked at $4.56M in Q3 2022.
392 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.